Clarity Pharmaceuticals Ltd
Clinical trials sponsored by Clarity Pharmaceuticals Ltd, explained in plain language.
A radiopharmaceutical company developing targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-break
- New 'See and Treat' approach targets Hard-to-Treat prostate cancer Results expected Sep 2026 (estimated)
- New scan could spot hidden prostate cancer early Results expected Dec 2026 (estimated)
-
New 'See and Treat' approach targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two copper-based drugs that work together: one helps doctors see prostate cancer tumors on scans, and the other delivers targeted radiation to kill them. The trial involves 54 men with a type of advanced prostate cancer that no longer responds to hormone therapy.…
Phase 1/2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread
Diagnosis Recruiting nowThis phase 3 trial tests a new radioactive imaging agent, 64Cu-SAR-bisPSMA, to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer will receive a single injection of the agent before their scheduled prost…
Phase 3 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC